Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
2.
Clin Exp Allergy ; 48(9): 1206-1213, 2018 09.
Article in English | MEDLINE | ID: mdl-29904971

ABSTRACT

BACKGROUND: The role of sensitization to commercially available allergens of English walnut (Juglans regia) Jug r 1, 2 and 3 in walnut allergy has been previously investigated in walnut allergic adults and was unable to explain all cases of walnut allergy. OBJECTIVES: Identify recognized walnut allergens, other than the ones previously investigated (Jug r 1-3), in walnut allergic adults and determine the sensitization frequency and diagnostic value. METHODS: Three different in-house walnut extracts were prepared and analysed on SDS-PAGE blots to identify allergenic walnut proteins. Immunoblots and immunoprecipitation, followed by LC-MS analysis, were performed to screen for, and confirm, IgE binding to walnut allergens in selected walnut allergic adults. In a cohort of 55 walnut challenged adults, including 33 allergic and 22 tolerant, sensitization to native and recombinant walnut allergen Jug r 4 was assessed using immunoblotting and immuno-line blot (EUROLINE), respectively. RESULTS: Screening of sera of 8 walnut allergic adults identified Jug r 4 as an allergen in our population. In the total cohort of 55 subjects, 5 were positive for Jug r 4 on immunoblot and 10 on EUROLINE. All but one EUROLINE positive subject had a positive food challenge (sensitivity 27%, specificity 95%, PPV 90%, NPV 47%). All 5 subjects positive on immunoblot were also positive on EUROLINE. LC-MS analysis showed a lack of Jug r 4 in the ImmunoCAP extract. Co-sensitization to other 11S albumins (eg hazelnut Cor a 9) was common in Jug r 4 sensitized subjects, potentially due to cross-reactivity. CONCLUSIONS: Walnut 11S globulin Jug r 4 is a relevant minor allergen, recognized by 27% of walnut allergic adults. It has a high positive predictive value of 90% for walnut allergy. Specific IgE against Jug r 4 occurred mostly with concomitant sensitization to other walnut components, mainly Jug r 1.


Subject(s)
Antigens, Plant/immunology , Juglans/adverse effects , Nut Hypersensitivity/immunology , Plant Proteins/immunology , Adult , Antigens, Plant/chemistry , Antigens, Plant/isolation & purification , Chromatography, Liquid , Cross Reactions/immunology , Female , Humans , Immunoassay , Immunoglobulin E/immunology , Juglans/chemistry , Male , Mass Spectrometry , Nut Hypersensitivity/diagnosis , Plant Extracts/chemistry , Plant Extracts/immunology , Plant Proteins/chemistry , Plant Proteins/isolation & purification , Sensitivity and Specificity , Skin Tests , Young Adult
3.
Clin Exp Allergy ; 48(7): 890-897, 2018 07.
Article in English | MEDLINE | ID: mdl-29542223

ABSTRACT

BACKGROUND: Screening for specific IgE against 2S albumin proteins Ara h 2 and 6 has good positive predictive value in diagnosing peanut allergy. From the third 2S member Ara h 7, 3 isoforms have been identified. Their allergenicity has not been elucidated. OBJECTIVE: This study investigated the allergenicity of Ara h 7 isoforms compared to Ara h 2 and 6. METHODS: Sensitization of 15 DBPCFC-confirmed peanut-allergic patients to recombinant Ara h 2.0201, Ara h 6.01 and isoforms of recombinant Ara h 7 was determined by IgE immunoblotting strips. A basophil activation test (BAT) was performed in 9 patients to determine IgE-cross-linking capacities of the allergens. Sensitivity to the allergens was tested in 5 patients who were sensitized to at least 1 Ara h 7 isoform, by a concentration range in the BAT. 3D prediction models and sequence alignments were used to visualize differences between isoforms and to predict allergenic epitope regions. RESULTS: Sensitization to Ara h 7.0201 was most frequent (80%) and showed to be equally potent as Ara h 2.0201 and 6.01 in inducing basophil degranulation. Sensitization to Ara h 7.0201 together with Ara h 2.0201 and/or 6.01 was observed, indicating the presence of unique epitopes compared to the other 2 isoforms. Differences between the 3 Ara h 7 isoforms were observed in C-terminal cysteine residues, pepsin and trypsin cleavage sites and 3 single amino acid substitutions. CONCLUSION & CLINICAL RELEVANCE: The majority of peanut-allergic patients are sensitized to isoform Ara h 7.0201, which is functionally as active as Ara h 2.0201 and 6.01. Unique epitopes are most likely located in the C-terminus or an allergenic loop region which is a known allergenic epitope region for Ara h 2.0201 and 6.01. Due to its unique epitopes and allergenicity, it is an interesting candidate to improve the diagnostic accuracy for peanut allergy.


Subject(s)
2S Albumins, Plant/immunology , Antigens, Plant/immunology , Basophils/immunology , Cell Degranulation/immunology , Epitopes/immunology , Peanut Hypersensitivity/immunology , 2S Albumins, Plant/chemistry , Adult , Amino Acid Sequence , Antigens, Plant/chemistry , Basophils/metabolism , Epitopes/chemistry , Female , Humans , Immunoglobulin E/immunology , Male , Middle Aged , Models, Molecular , Peanut Hypersensitivity/diagnosis , Protein Conformation , Protein Isoforms , Structure-Activity Relationship
4.
Am J Transplant ; 18(9): 2274-2284, 2018 09.
Article in English | MEDLINE | ID: mdl-29464832

ABSTRACT

The presence of donor-specific anti-HLA antibodies (DSAs) is associated with increased risk of graft failure after kidney transplant. We hypothesized that DSAs against HLA class I, class II, or both classes indicate a different risk for graft loss between deceased and living donor transplant. In this study, we investigated the impact of pretransplant DSAs, by using single antigen bead assays, on long-term graft survival in 3237 deceased and 1487 living donor kidney transplants with a negative complement-dependent crossmatch. In living donor transplants, we found a limited effect on graft survival of DSAs against class I or II antigens after transplant. Class I and II DSAs combined resulted in decreased 10-year graft survival (84% to 75%). In contrast, after deceased donor transplant, patients with class I or class II DSAs had a 10-year graft survival of 59% and 60%, respectively, both significantly lower than the survival for patients without DSAs (76%). The combination of class I and II DSAs resulted in a 10-year survival of 54% in deceased donor transplants. In conclusion, class I and II DSAs are a clear risk factor for graft loss in deceased donor transplants, while in living donor transplants, class I and II DSAs seem to be associated with an increased risk for graft failure, but this could not be assessed due to their low prevalence.


Subject(s)
Donor Selection , Graft Rejection/mortality , HLA Antigens/immunology , Isoantibodies/adverse effects , Kidney Failure, Chronic/surgery , Kidney Transplantation/mortality , Living Donors , Adult , Cadaver , Female , Follow-Up Studies , Graft Rejection/etiology , Graft Rejection/pathology , Graft Survival , Humans , Kidney Transplantation/adverse effects , Male , Middle Aged , Postoperative Complications , Prognosis , Retrospective Studies , Risk Factors , Survival Rate
5.
Clin Exp Allergy ; 48(1): 60-65, 2018 01.
Article in English | MEDLINE | ID: mdl-28906044

ABSTRACT

BACKGROUND: Little is known on the clinical relevance of peanut 2S albumin Ara h 7. OBJECTIVE: To investigate the discriminative ability of Ara h 7 in peanut allergy and assess the role of cross-reactivity between Ara h 2, 6 and Ara h 7 isoforms. METHODS: Sensitization to recombinant peanut storage proteins Ara h 1, 2, 3, 6, and 7 was assessed using a line blot in sera from 40 peanut-tolerant and 40 peanut-allergic patients, based on food challenge outcome. A dose-dependent ELISA inhibition experiment was performed with recombinant Ara h 2, 6 and Ara h 7 isoforms. RESULTS: For Ara h 7.0201, an area under the ROC curve was found of 0.83, comparable to Ara h 2 (AUC 0.81) and Ara h 6 (AUC 0.85). Ara h 7 intensity values strongly correlated with those from Ara h 2 and 6 (rs = 0.81). Of all patients sensitized to 2S albumins Ara h 2, 6, or 7, the majority was co-sensitized to all three (n = 24, 68%), although mono-sensitization to either 2S albumin was also observed in selected patients (Ara h 2: n = 6, 17%; Ara h 6: n = 2, 6%; Ara h 7: n = 2, 6%). Binding to Ara h 7.0101 could be strongly inhibited by Ara h 7.0201, but not the other way around. CONCLUSIONS AND CLINICAL RELEVANCE: Specific IgE against Ara h 7.0201 has a predictive ability for peanut allergy similar to Ara h 2 and 6 and possesses unique IgE epitopes as well as epitopes shared between the other Ara h 7 isoform and Ara h 2 and 6. While co-sensitization to all three 2S albumins is most common, mono-sensitization to either Ara h 2, 6, or 7 occurs in selected patients, leading to a risk of misdiagnosis when testing for a single 2S albumin.


Subject(s)
2S Albumins, Plant/immunology , Antigens, Plant/immunology , Epitopes/immunology , Immunoglobulin E/immunology , Peanut Hypersensitivity/immunology , Adolescent , Adult , Aged , Cross Reactions , Female , Humans , Male , Middle Aged
6.
Clin Rev Allergy Immunol ; 54(3): 412-431, 2018 Jun.
Article in English | MEDLINE | ID: mdl-27672078

ABSTRACT

Non-hereditary angioedema (AE) with normal C1 esterase inhibitor (C1INH) can be presumably bradykinin- or mast cell-mediated, or of unknown cause. In this systematic review, we searched PubMed, EMBASE, and Scopus to provide an overview of the efficacy of different treatment options for the abovementioned subtypes of refractory non-hereditary AE with or without wheals and with normal C1INH. After study selection and risk of bias assessment, 61 articles were included for data extraction and analysis. Therapies were described for angiotensin-converting enzyme inhibitor-induced AE (ACEi-AE), for idiopathic AE, and for AE with wheals. Described treatments consisted of ecallantide, icatibant, C1INH, fresh frozen plasma (FFP), tranexamic acid (TA), and omalizumab. Additionally, individual studies for anti-vitamin K, progestin, and methotrexate were found. Safety information was available in 26 articles. Most therapies were used off-label and in few patients. There is a need for additional studies with a high level of evidence. In conclusion, in acute attacks of ACEi-AE and idiopathic AE, treatment with icatibant, C1INH, TA, and FFP often leads to symptom relief within 2 h, with limited side effects. For prophylactic treatment of idiopathic AE and AE with wheals, omalizumab, TA, and C1INH were effective and safe in the majority of patients.


Subject(s)
Angioedema/therapy , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Bradykinin/analogs & derivatives , Omalizumab/therapeutic use , Tranexamic Acid/therapeutic use , Bradykinin/therapeutic use , Humans , Progestins/therapeutic use , Treatment Outcome
7.
Transpl Immunol ; 42: 1-4, 2017 06.
Article in English | MEDLINE | ID: mdl-28457921

ABSTRACT

Lung transplantation (LTx) is the last treatment for patients suffering from end-stage lung diseases. Survival post-LTx is hampered by the development of the bronchiolitis obliterans syndrome (BOS) and diagnosis is often late. Given the urgent clinical need to recognize BOS patients at an early stage, we analyzed circulating miRNAs to identify possible stratification markers for BOS development post-transplantation. Therefore, pro-fibrotic (miR-21, miR-155), anti-fibrotic (miR-29a) and fibrosis-unrelated (miR-103, miR-191) miRNAs were analyzed in serum of end-stage lung disease patients and during LTx follow-up. Significant elevated levels of serum miRNAs were observed for all investigated miRNAs in both chronic obstructive pulmonary disease and interstitial lung disease patients compared to healthy controls. The same miRNAs were also significantly increased in the serum of BOS+ vs. BOS- patients. Most importantly, miR-21, miR-29a, miR-103, and miR-191 levels were significantly higher in BOS+ patients prior to clinical BOS diagnosis. We demonstrated that a selected group of miRNAs investigated is elevated in end-stage lung disease and BOS+ patients, prior to clinical BOS diagnosis. Even if further research is expedient on the prognostic value of circulating miRNAs in BOS and lung conditions in general, these results strongly suggest that circulating miRNAs could be used as potential biomarkers for BOS development.


Subject(s)
Bronchiolitis Obliterans/blood , Lung Transplantation , MicroRNAs/blood , Adult , Biomarkers/blood , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pulmonary Disease, Chronic Obstructive/blood , Retrospective Studies
8.
Am J Transplant ; 17(8): 2000-2007, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28097805

ABSTRACT

The complement system, as part of the innate immune system, plays an important role in renal transplantation. Complement is involved in the protection against foreign organisms and clearance of apoptotic cells but can also cause injury to the renal allograft, for instance, via antibody binding or in ischemia-reperfusion injury. Numerous polymorphisms in complement factors have been identified thus far; some of them result in different functionalities or alter complement levels. In this review, we provide an overview of the literature on the role of complement polymorphisms in renal transplantation. Furthermore, we discuss functional complement polymorphisms that have not yet been investigated in kidney transplantation. By investigating multiple polymorphisms both in donor and recipient at the same time, a complotype can be constructed. Because the combination of multiple polymorphisms is likely to have a greater impact than a single one, this could provide valuable prognostic information.


Subject(s)
Complement System Proteins/genetics , Graft Rejection/immunology , Kidney Transplantation , Polymorphism, Genetic , Complement System Proteins/immunology , Humans
9.
Am J Transplant ; 17(1): 246-254, 2017 01.
Article in English | MEDLINE | ID: mdl-27428759

ABSTRACT

Cardiac allograft vasculopathy (CAV) is a transplant pathology, limiting graft survival after heart transplantation. CAV arteries are surrounded by ectopic lymphoid structures (ELS) containing B cells and plasma cells. The aim of this study was to characterize the antigenic targets of antibodies produced in ELS. Coronary arteries and surrounding epicardial tissue from 56 transplant recipients were collected during autopsy. Immunofluorescence was used to identify antibody-producing plasma cells. Immunoglobulin levels in tissue lysates were measured by enzyme-linked immunosorbent assay and analyzed for donor-specific HLA antibodies by Luminex assay. Cytokine and receptor expression levels were quantified using quantitative polymerase chain reaction. Plasma cells in ELS were polyclonal and produced IgG and/or IgM antibodies. In epicardial tissue, IgG (p < 0.05) and IgM levels were higher in transplant patients with larger ELS than smaller ELS. In 4 of 21 (19%) patients with ELS, donor-specific HLA type II antibodies were detected locally. Cytokine and receptor expression (CXCR3, interferon γ and TGF-ß) was higher in large ELS in the epicardial tissue than in other vessel wall layers, suggesting active recruitment and proliferation of T and B lymphocytes. ELS exhibited active plasma cells producing locally manufactured antibodies that, in some cases, were directed against the donor HLA, potentially mediating rejection with major consequences for the graft.


Subject(s)
Graft Rejection/etiology , Graft Survival/immunology , Heart Transplantation/adverse effects , Isoantibodies/blood , Isoantibodies/immunology , Lymphoid Tissue/immunology , Tissue Donors , Allografts , Female , Graft Rejection/pathology , Histocompatibility Testing , Humans , Male , Prognosis , Risk Factors
10.
HLA ; 88(3): 110-9, 2016 09.
Article in English | MEDLINE | ID: mdl-27534609

ABSTRACT

Solid-phase multiplex-bead assays are widely used in transplantation to detect anti-human leukocyte antigen (HLA) antibodies. These assays enable high resolution detection of low levels of HLA antibodies. However, multiplex-bead assays are costly and yield variable measurements that limit the comparison of results between laboratories. In the context of a Dutch national Consortium study we aimed to determine the inter-assay and inter-machine variability of multiplex-bead assays, and we assessed how to reduce the assay reagents costs. Fifteen sera containing a variety of HLA antibodies were used yielding in total 7092 median fluorescence intensities (MFI) values. The inter-assay and inter-machine mean absolute relative differences (MARD) of the screening assay were 12% and 13%, respectively. The single antigen bead (SAB) inter-assay MARD was comparable, but showed a higher lot-to-lot variability. Reduction of screening assay reagents to 50% or 40% of manufacturers' recommendations resulted in MFI values comparable to 100% of the reagents, with an MARD of 12% or 14%, respectively. The MARD of the 50% and 40% SAB assay reagent reductions were 11% and 22%, respectively. From this study, we conclude that the reagents can be reliably reduced at least to 50% of manufacturers' recommendations with virtually no differences in HLA antibody assignments.


Subject(s)
Automation, Laboratory/economics , HLA Antigens/immunology , Immunoassay/economics , Isoantibodies/blood , Reagent Kits, Diagnostic/economics , Alleles , Automation, Laboratory/standards , HLA Antigens/blood , Histocompatibility Testing , Humans , Immune Sera/chemistry , Immunoassay/standards , Kidney Transplantation , Observer Variation , Reproducibility of Results , Sensitivity and Specificity
11.
Am J Transplant ; 16(3): 987-98, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26517734

ABSTRACT

Complement activation leads primarily to membrane attack complex formation and subsequent target cell lysis. Protection against self-damage is regulated by complement regulatory proteins, including CD46, CD55, and CD59. Within their promoter regions, single-nucleotide polymorphisms (SNPs) are present that could influence transcription. We analyzed these SNPs and investigated their influence on protein expression levels. A single SNP configuration in the promoter region of CD59 was found correlating with lower CD59 expression on lung endothelial cells (p = 0.016) and monocytes (p = 0.013). Lung endothelial cells with this SNP configuration secreted more profibrotic cytokine IL-6 (p = 0.047) and fibroblast growth factor ß (p = 0.036) on exposure to sublytic complement activation than cells with the opposing configuration, whereas monocytes were more susceptible to antibody-mediated complement lysis (p < 0.0001). Analysis of 137 lung transplant donors indicated that this CD59 SNP configuration correlates with impaired long-term survival (p = 0.094) and a significantly higher incidence of bronchiolitis obliterans syndrome (p = 0.046) in the recipient. These findings support a role for complement in the pathogenesis of this posttransplant complication and are the first to show a deleterious association of a donor CD59 promoter polymorphism in lung transplantation.


Subject(s)
CD59 Antigens/genetics , Graft Rejection/diagnosis , Lung Transplantation , Polymorphism, Genetic/genetics , Postoperative Complications , Promoter Regions, Genetic/genetics , Tissue Donors , Adolescent , Adult , Complement Activation , Female , Follow-Up Studies , Graft Rejection/etiology , Graft Survival , Humans , Male , Middle Aged , Monocytes/cytology , Monocytes/metabolism , Prognosis , Survival Rate , Young Adult
12.
J Cyst Fibros ; 14(1): 42-5, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25096855

ABSTRACT

Autoantibodies against endothelin-1 type A receptor (ETAR) are present in systemic sclerosis complicated by lung fibrosis and pulmonary hypertension. As increased serum levels and local overproduction of endothelin-1 in the airways are reported in cystic fibrosis (CF) patients, we reasoned that anti-ETAR antibodies could be prevalent in endstage CF patients prior to lung transplantation (LTx). Also, ETAR autoantibodies are frequently associated with autoantibodies against the angiotensin II type 1 receptor (AT1R). We analyzed the presence of anti-ETAR and anti-AT1R autoantibodies in 43 LTx patients (chronic obstructive pulmonary disease (COPD), n=20; CF, n=13; interstitial lung disease (ILD), n=1). We observed overall higher anti-ETAR and anti-AT1R autoantibody titers in sera taken prior to LTx in the CF patient group as compared to COPD. No difference was found in autoantibody levels between patients with CF versus ILD. In sera taken post-LTx we found the same difference in anti-ETAR and anti-AT1R autoantibody titers between patients with CF versus COPD. No difference was found in antibody titers between sera taken prior to or 6 months after LTx. There was no association between autoantibody levels and other relevant demographic parameters, and we found no association between autoantibody titers and the development of the bronchiolitis obliterans syndrome. Both autoantibody titers were strongly correlated. We hypothesize that due to prolonged exposure to bacterial infection, increased levels of AT1R and ETAR result in a deregulated immune response causing autoantibody formation. Further research is expedient to elucidate the occurrence of autoantibodies against ETAR and AT1R and their role in disease progression.


Subject(s)
Autoantibodies/immunology , Cystic Fibrosis/immunology , Cystic Fibrosis/surgery , Receptor, Angiotensin, Type 1/metabolism , Receptor, Endothelin A/metabolism , Adolescent , Adult , Biomarkers/blood , Cohort Studies , Cystic Fibrosis/blood , Enzyme-Linked Immunosorbent Assay , Female , Humans , Lung Diseases, Interstitial/blood , Lung Diseases, Interstitial/immunology , Lung Transplantation/methods , Male , Middle Aged , Patient Selection , Pilot Projects , Prognosis , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/immunology , Receptor, Angiotensin, Type 1/immunology , Receptor, Endothelin A/blood , Retrospective Studies , Risk Assessment , Severity of Illness Index , Young Adult
13.
Transpl Immunol ; 31(4): 184-90, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25258025

ABSTRACT

Kidney transplantation is the best treatment option for patients with end-stage renal failure. At present, approximately 800 Dutch patients are registered on the active waiting list of Eurotransplant. The waiting time in the Netherlands for a kidney from a deceased donor is on average between 3 and 4 years. During this period, patients are fully dependent on dialysis, which replaces only partly the renal function, whereas the quality of life is limited. Mortality among patients on the waiting list is high. In order to increase the number of kidney donors, several initiatives have been undertaken by the Dutch Kidney Foundation including national calls for donor registration and providing information on organ donation and kidney transplantation. The aim of the national PROCARE consortium is to develop improved matching algorithms that will lead to a prolonged survival of transplanted donor kidneys and a reduced HLA immunization. The latter will positively affect the waiting time for a retransplantation. The present algorithm for allocation is among others based on matching for HLA antigens, which were originally defined by antibodies using serological typing techniques. However, several studies suggest that this algorithm needs adaptation and that other immune parameters which are currently not included may assist in improving graft survival rates. We will employ a multicenter-based evaluation on 5429 patients transplanted between 1995 and 2005 in the Netherlands. The association between key clinical endpoints and selected laboratory defined parameters will be examined, including Luminex-defined HLA antibody specificities, T and B cell epitopes recognized on the mismatched HLA antigens, non-HLA antibodies, and also polymorphisms in complement and Fc receptors functionally associated with effector functions of anti-graft antibodies. From these data, key parameters determining the success of kidney transplantation will be identified which will lead to the identification of additional parameters to be included in future matching algorithms aiming to extend survival of transplanted kidneys and to diminish HLA immunization. Computer simulation studies will reveal the number of patients having a direct benefit from improved matching, the effect on shortening of the waiting list, and the decrease in waiting time.


Subject(s)
Histocompatibility Testing/methods , Kidney Failure, Chronic/surgery , Kidney Transplantation/mortality , Tissue and Organ Procurement/methods , Waiting Lists , Epitopes, B-Lymphocyte/immunology , Epitopes, T-Lymphocyte/immunology , Graft Rejection/immunology , Graft Survival/immunology , HLA Antigens/immunology , Humans , Kidney/immunology , Kidney/surgery , Quality of Life , Renal Dialysis
14.
Transpl Immunol ; 31(4): 260-5, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25195091

ABSTRACT

Lung transplantation (LTx) is the final treatment option for patients with endstage lung diseases including chronic obstructive pulmonary disease, cystic fibrosis, and interstitial lung disease. Survival after LTx is severely hampered by the development of the bronchiolitis obliterans syndrome (BOS) which is hallmarked by excessive fibrosis and scar tissue formation leading to small airway obliteration and eventually organ failure. The pathophysiology of BOS is incompletely understood. During the past years both anti-HLA and non-HLA antibodies have been identified that correlate with transplantation outcome. Also, the involvement of autoimmunity on BOS progression has been demonstrated, including autoantigens Type V collagen and K-alpha tubulin. Both allo- and autoantibodies binding to its respective antigen trigger the binding of C1q and sequential complement activation which can lead to either cell damage or activation, both processes which fit into the current model of BOS pathogenesis. In this review we will discuss both HLA, non-HLA and autoantibodies associated with disease progression, but also elaborate on the subsequent complement effector mechanisms, complement regulation, and the potential influence of regulatory mechanisms on graft survival.


Subject(s)
Autoimmunity/immunology , Bronchiolitis Obliterans/immunology , Complement C1q/immunology , Graft Rejection/immunology , Lung Transplantation/adverse effects , Autoantibodies/immunology , Autoantigens/immunology , Collagen Type V/immunology , Complement Activation/immunology , HLA Antigens/immunology , Humans , Immunity, Humoral/immunology , Lung/immunology , Lung/pathology , Lung/surgery , Tubulin/immunology
15.
J Cyst Fibros ; 13(3): 281-8, 2014 May.
Article in English | MEDLINE | ID: mdl-24269518

ABSTRACT

BACKGROUND: Bactericidal/permeability increasing protein fold containing family A (BPIFA) 1, is a secreted protein of the upper airways that shares structural homology with BPI and exhibits comparable antimicrobial capacities. We hypothesized that CF patients have circulating IgG or IgA anti-BPIFA1 autoantibodies, similarly as reported for BPI autoantibodies. METHODS: We analyzed pre- and post-transplantation sera from 67 endstage lung disease patients who underwent lung transplantation (LTx) because of COPD (n=27), CF (n=25), and ILD (n=15). RESULTS: Anti-BPIFA1 (48%) and anti-BPI (92%) were elevated in CF patients compared to healthy controls, with anti-BPIFA1 IgG isotype being most prevalent, whereas anti-BPI is of the IgA isotype. Levels of anti-BPI autoantibodies significantly declined post-LTx, whereas anti-BPIFA1 did not. No relation was found between autoantibodies against BPIFA1 and BPI. CONCLUSION: Our results indicate that BPIFA1 is a novel target for autoantibodies in CF. The function of these autoantibodies needed to be investigated in future studies.


Subject(s)
Autoantibodies/immunology , Cystic Fibrosis/immunology , Glycoproteins/immunology , Phosphoproteins/immunology , Pulmonary Disease, Chronic Obstructive/immunology , Adolescent , Adult , Cohort Studies , Cystic Fibrosis/epidemiology , Cystic Fibrosis/surgery , Female , Homeodomain Proteins/immunology , Humans , Immunoglobulin A/immunology , Immunoglobulin G/immunology , Lung Transplantation , Male , Middle Aged , Pulmonary Disease, Chronic Obstructive/epidemiology , Pulmonary Disease, Chronic Obstructive/surgery , Rheumatoid Factor/immunology , Seroepidemiologic Studies , Transcription Factors/immunology , Young Adult
16.
Clin Exp Immunol ; 173(3): 536-43, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23627692

ABSTRACT

Antibodies recognizing denatured human leucocyte antigen (HLA) can co-react with epitopes on intact HLA or recognize cryptic epitopes which are normally unaccessible to HLA antibodies. Their specificity cannot be distinguished by single antigen beads (SAB) alone, as they carry a mixture of intact and denatured HLA. In this study, we selected pretransplant sera containing donor-specific HLA class I antibodies (DSA) according to regular SAB analysis from 156 kidney transplant recipients. These sera were analysed using a SAB preparation (iBeads) which is largely devoid of denatured HLA class I, and SAB coated with denatured HLA class I antigens. A total of 241 class I DSA were found by regular SAB analysis, of which 152 (63%) were also found by iBeads, whereas 28 (11%) were caused by reactivity with denatured DNA. Patients with DSA defined either by regular SAB or iBeads showed a significantly lower graft survival rate (P = 0·007) compared to those without HLA class I DSA, whereas reactivity to exclusively denatured HLA was not associated with decreased graft survival. In addition, DSA defined by reactivity to class I SAB or class I iBeads occurred more frequently in female patients and in patients with historic HLA sensitization, whereas reactivity to denatured HLA class I was not associated with any of these parameters. Our data suggest that pretransplant donor-specific antibodies against denatured HLA are clinically irrelevant in patients already sensitized against intact HLA.


Subject(s)
HLA Antigens/immunology , Isoantibodies/immunology , Kidney Transplantation/immunology , Tissue Donors , Adult , Antibody Specificity/immunology , Female , Graft Rejection/immunology , Graft Survival/immunology , HLA Antigens/chemistry , Humans , Isoantibodies/blood , Male , Middle Aged , Protein Binding/immunology , Protein Denaturation
17.
Am J Transplant ; 12(6): 1618-23, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22404993

ABSTRACT

Pretransplant risk assessment of graft failure is important for donor selection and choice of immunosuppressive treatment. We examined the relation between kidney graft failure and presence of IgG donor specific HLA antibodies (DSA) or C1q-fixing DSA, detected by single antigen bead array (SAB) in pretransplant sera from 837 transplantations. IgG-DSA were found in 290 (35%) sera, whereas only 30 (4%) sera had C1q-fixing DSA. Patients with both class-I plus -II DSA had a 10 yr graft survival of 30% versus 72% in patients without HLA antibodies (p < 0.001). No significant difference was observed in graft survival between patients with or without C1q-fixing DSA. Direct comparison of both assays showed that high mean fluorescence intensity values on the pan-IgG SAB assay are generally related to C1q-fixation. We conclude that the presence of class-I plus -II IgG DSA as detected by SAB in pretransplant sera of crossmatch negative kidney recipients is indicative for an increased risk for graft failure, whereas the clinical significance of C1q-fixing IgG-DSA could not be assessed due to their low prevalence.


Subject(s)
Graft Rejection , Histocompatibility Antigens Class II/immunology , Histocompatibility Antigens Class I/immunology , Kidney Transplantation , Humans , Risk Factors
18.
Clin Exp Immunol ; 166(1): 103-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21910727

ABSTRACT

Alloreactive T cells that infiltrate the graft after lung transplantation (LTx) play a role in chronic rejection. Chemokines such as thymus and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC) and monocyte chemotactic protein-1 (MCP-1) are produced locally in the lung and attract T cells via chemokine receptor 4 (CCR4). In a TARC gradient, cells expressing CCR4(++) migrate more efficiently than CCR4(+) -expressing cells. In this study, we compared the CCR4 expression of T cells in blood from 20 lung transplant recipients to healthy controls. We then examined whether CCR4 expression is associated with the occurrence of chronic rejection. The CCR4(++) expression was decreased on CD4 T cells from LTx patients (P < 0·0001) when compared to healthy controls. The analysis of CD4 T cell subsets showed that this decrease was present on central memory, effector memory and terminally differentiated T cells (P = 0·0007, P < 0·0001 and P = 0·05, respectively), while a trend was found for naive CD4 T cells (P = 0·06). Also, the expression of CCR4(+) on regulatory T cells (T(regs) ) was decreased in LTx patients when compared to healthy controls (P = 0·02). Interestingly, the CCR4(++) expression on CD4 effector memory T cells was decreased in patients developing chronic rejection sometimes more than a year before the clinical diagnosis when compared to patients who did not (P = 0·04). The analysis of CD8 T cell subsets only showed the CCR4(+) expression to be increased significantly on effector memory and terminally differentiated CD8 T cells (P = 0·02, P = 0·03, respectively) in LTx patients, but no relation was found in chronic rejection. In conclusion, the expression of CCR4 on T cell subsets was altered after LTx and appears to be related to chronic rejection.


Subject(s)
Bronchiolitis Obliterans/immunology , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/metabolism , Graft Rejection/blood , Lung Transplantation/immunology , Receptors, CCR4 , Adult , Biomarkers/blood , Bronchiolitis Obliterans/blood , Bronchiolitis Obliterans/etiology , Bronchiolitis Obliterans/pathology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Case-Control Studies , Cell Movement/immunology , Cells, Cultured , Chemokine CCL17/biosynthesis , Chemokine CCL17/immunology , Chemokine CCL2/biosynthesis , Chemokine CCL2/immunology , Chemokine CCL22/biosynthesis , Chemokine CCL22/immunology , Female , Flow Cytometry , Graft Rejection/immunology , Graft Rejection/pathology , Humans , Lung Transplantation/adverse effects , Lung Transplantation/pathology , Male , Middle Aged , Receptors, CCR4/biosynthesis , Receptors, CCR4/blood , Receptors, CCR4/immunology , Syndrome , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Time Factors
19.
Clin Exp Immunol ; 165(3): 410-6, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21707593

ABSTRACT

Despite the use of immunosuppressives mainly influencing T and B cell responses, the prevalence of the bronchiolitis obliterans syndrome (BOS) after lung transplantation is high. Mannose-binding lectin (MBL) is a pattern recognition molecule of complement and an important component of the innate immunity. MBL is associated with rejection, infection and survival in other solid organ transplantations. In this study the relation between functional MBL levels and cytomegalovirus (CMV) reactivations and the development of BOS and survival after lung transplantation was investigated. MBL levels were measured in 85 patients before and in 57 of these patients after lung transplantation. The relation of MBL on survival, CMV reactivation and the development of BOS were investigated with Kaplan-Meier (log-rank) survival analysis. MBL levels decreased on average by 20% (P < 0·001) after transplantation and eventually returned to pretransplant levels. Fourteen of the 85 patients had deficient pretransplant MBL levels and these patients had a tendency towards a better survival compared to those with normal MBL levels (P = 0·08). Although no correlation was found between MBL deficiency and the development of BOS, more CMV reactivations occurred in recipients with deficient versus normal levels of MBL (P = 0·03). Our results suggest that MBL deficiency is associated with CMV reactivations and a longer overall survival, but not with the development of BOS.


Subject(s)
Cytomegalovirus/physiology , Lung Transplantation/mortality , Mannose-Binding Lectin/deficiency , Virus Activation , Adolescent , Adult , Bronchiolitis Obliterans/diagnosis , Cytomegalovirus/immunology , Cytomegalovirus/isolation & purification , Female , Ganciclovir/analogs & derivatives , Ganciclovir/therapeutic use , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Kaplan-Meier Estimate , Lung Transplantation/immunology , Male , Mannose-Binding Lectin/blood , Middle Aged , Postoperative Complications/diagnosis , Postoperative Complications/virology , Retrospective Studies , Risk Factors , Survival Rate , Valganciclovir , Young Adult
20.
Neurology ; 74(10): 828-32, 2010 Mar 09.
Article in English | MEDLINE | ID: mdl-20211906

ABSTRACT

OBJECTIVES: The favorable response to treatment with IV immunoglobulins and the presence of IgM antibodies to the glycolipid GM1 are indications that inflammation underlies multifocal motor neuropathy (MMN) pathogenesis. We investigated the association of MMN with human leukocyte antigen (HLA) class I and II antigens. METHODS: HLA class I and II antigens of 74 Dutch patients with MMN and 700 controls were determined in a case-control study. Associations of HLA types with MMN disease characteristics were investigated. RESULTS: Compared with controls, patients with MMN had higher frequencies of HLA-DRB1*15 (41 vs 24%, p = 0.0017). Disease characteristics were not associated with specific HLA types. CONCLUSIONS: Similar associations were found in patients with multiple sclerosis and women with chronic immune-mediated demyelinating neuropathy, which may suggest that these demyelinating disorders share pathogenic mechanisms.


Subject(s)
HLA-DQ Antigens/genetics , HLA-DR Antigens/genetics , Membrane Glycoproteins/genetics , Multiple Sclerosis/genetics , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/genetics , Adult , Age Factors , Aged , Brachial Plexus/pathology , Case-Control Studies , Chi-Square Distribution , Female , G(M1) Ganglioside/immunology , HLA-DQ beta-Chains , HLA-DRB1 Chains , Humans , Immunoglobulin M/blood , Magnetic Resonance Imaging/methods , Male , Middle Aged , Multiple Sclerosis/pathology , Multiple Sclerosis/physiopathology , Neural Conduction/physiology , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/pathology , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/physiopathology , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...